Form 4: DexCom Director Sells Shares Under 10b5-1 Plan

DexCom Director Richard Collins sold 2,906 shares of common stock for $59.05 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Richard Alexander Collins, a Director of DexCom Inc. (DXCM), reported the sale of 2,906 shares of common stock.
• The transaction occurred on November 14, 2025, at a price of $59.05 per share.
• The sale was executed pursuant to a Rule 10b5-1 Plan adopted by the Richard A. Collins Revocable Trust on August 7, 2025, designed for the orderly disposition of shares.
• Following this transaction, Collins beneficially owns 35,088 shares indirectly through the Trust and 5,074 unvested restricted stock units directly.
• The unvested restricted stock units were granted on May 8, 2025, and will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: A neutral score as the filing is a routine disclosure of an insider stock sale under a pre-arranged 10b5-1 plan, which is generally not indicative of strong positive or negative sentiment regarding the company's prospects.

Positives

• The sale was conducted under a pre-arranged 10b5-1 plan, indicating a planned disposition rather than a reaction to new, adverse information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's stock transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the medical device sector. It reflects an individual director's portfolio management rather than a company-wide strategic move.

Related Party Transactions

• The sale of shares was conducted by the Richard A. Collins Revocable Trust, with respect to which Richard Alexander Collins is a trustee. This constitutes a transaction by a related party (the director's trust).

Stakeholder Impact

• Shareholders: The sale by a director, even under a 10b5-1 plan, might be viewed with slight caution by some investors, though the pre-planned nature mitigates concerns about opportunistic selling. The director retains significant holdings.

Next Steps

• Vesting of 5,074 unvested restricted stock units on the earlier of May 8, 2026, or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

The filing details a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is a common practice for managing personal portfolios and does not typically signal a change in the company's fundamental outlook. While a director selling shares can sometimes be a minor negative signal, the planned nature of the transaction mitigates concerns about opportunistic selling. The director retains substantial beneficial ownership, including unvested restricted stock units. Therefore, this specific filing does not provide sufficient new information to warrant a change from a 'hold' position, assuming existing investment theses remain intact.

Keywords

DexCom, DXCM, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Richard Collins, Medical Devices